" class="no-js "lang="en-US"> Prashant Warier - Medtech Alert
Saturday, August 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Prashant Warier

Prashant Warier

About Prashant Warier

Prashant is an expert in the field of Artificial Intelligence and Deep learning. He has architected and commercialized several data science solutions in his 19 year career. He is also a prolific researcher, author, and speaker on topics related to data science and machine learning. He is passionate about using deep learning to make healthcare affordable and accessible.

Related Story

Artificial Intelligence

 Qure.ai Bags Second FDA Clearance for Brain CT Scan AI | Pharmtech Focus

Qure.ai Bags Second FDA Clearance for Brain CT Scan AI

August 25 2021

Leading medical image AI provider Qure.ai has announced US FDA 510(k) clearance for its Brain CT quantification […]